tirzepatide mash phase 3 The first major RCT directly comparing vs semaglutide is out. Tirzepatide showed superior HbA1c reduction and weight loss. Here's why the dual mechanism matters. Published in NEJM. Educational content Calorie control Flavor:GLP-1 Craving Control Set Semaglutide + HRT -

tirzepatide mash phase 3 The first major RCT directly comparing vs semaglutide is out. Tirzepatide showed superior HbA1c reduction and weight loss. Here's why the dual mechanism matters. Published in NEJM. Educational content Calorie control Flavor:GLP-1 Craving Control Set Semaglutide + HRT -

Semaglutide + HRT - is it right for you? #menopause @drsalaswhalen

The case for plausible benefit: Many mechanisms (weight loss, blood pressure, inflammation) are not diabetes-specific Obesity-related kidney disease is common in non-diabetic CKD Cardiovascular benefits (SELECT trial) are independent of diabetes The case for uncertainty: FLOW did not enroll non-diabetic patients Hyperglycemia is a major driver in DKD that is absent in many non-diabetic CKD cases The optimal dose for non-diabetic CKD may differ from the 1.0 mg used in FLOW Dedicated trials in non-diabetic CKD are in design

Calorie control

Flavor:GLP-1 Craving Control Set

What role do diet and exercise play during a Flow Wellness program